Sustained release PCO a b s t r a c t Docetaxel-loaded sustained-release preparation based on 2-Hydroxyethyl methacrylate (HEMA) and Methyl methacrylate (MMA) cross-linked copolymer (P(HEMA-co-MMA)) was prepared to examine the potential use for preventing posterior capsule opacification (PCO).
The preparations were prepared by polymerizing the mixture of HEMA, MMA, cross-linking agent (EGDMA), initiator (AIBN) and docetaxel. The influence factors and mechanism of drug release were studied in the experiments. FT-IR, X-RD and SEM methods were used to characterize the polymer (P(HEMA-co-MMA)) and docetaxel-loaded sustained-release preparations. Biocompatibility of P(HEMA-co-MMA) and in-vitro effect of docetaxel-loaded sustained-release preparations were also evaluated. The results showed that docetaxel could release sustainedly from these preparations prepared by cross-linking polymerization. And the release rate could be accelerated by increasing the MMA ratio or EGDMA ratio of the polymer. Release mechanism of docetaxel fitted the Higuchi model well. The results of IR and X-RD showed that only a hydrogen bond was formed between docetaxel and P(HEMA-co-MMA). Docetaxel dispersed in P(HEMA-co-MMA) in amorphous form. The elution test showed that P(HEMA-co-MMA) had good biocompatibility and the in-vitro pharmacodynamics study proved that docetaxel could release stably from the preparations and inhibit HLECs' proliferation. The docetaxel-loaded sustained-release preparations proved to be a promising therapy for preventing PCO. These results also lay a theoretical and experimental foundation for the future. ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All rights reserved.
1.

Introduction
By far, cataracts are the most common cause of low visual acuity. It is effectively treated by surgical procedure i.e. Phacoemulsification or Extra-Capsular Cataract Extraction (ECCE). However, the incidence of Posterior Capsule Opacification (PCO) is up to 50% in adults and 100% in children [1e3] , and it is a routine complication. It is caused by the proliferation and migration of the residual lens epithelial cells (LECs) left during the cataract surgery. As soon as PCO occurs, Nd:YAG laser must be used to treat the complication. But additional surgery involves additional expenses and mortgages. Moreover, this procedure may also cause rhegmatogenous retinal detachment or endophthalmitis. What's more, it is somewhat difficult to treat dense capsular opacification after operation for congenital cataract by Nd:YAG laser in infancy [1] . Thus, it is necessary to develop a non-surgical method to prevent PCO. Pharmacologic agents have been studied to prevent PCO for their inexpensive, convenient and digestible.
Many drugs such as Genipin, Proteasome inhibitors, Lithium, Mitomycin C, 5-FU and Diclofenac [4e18] display a strong inhibitory effect on LECs' proliferation as well as their serious toxicity to other intraocular structure. In order to reduce the toxicity of pharmacologic agents, some researchers irrigated the capsular bag for a few minutes with pharmacologic agents after phacoemulsification [12, 19] . Maloof AJ et al. developed a Sealed Capsule Irrigation (SCI) device [3, 9, 20] . Weidmann A and Xie L et al. developed sustained release preparations such as microspheres, microcapsules [10, 21, 22] , liposomes [23, 24] and drug-surface-modified intraocular lenses [25e27] . All of these methods could reduce the incidence of PCO, but they all had their own defects [28e30].
Hydrophilicity acrylic ester made from HEMA and MMA by chemical cross-linking copolymerization is a kind of non-degradation material, which has been widely used in medicine. Due to such properties as non-toxicity, nonantigen and satisfactory biocompatibility, it has been used as the materials of many medical products such as intraocular lenses [31e34], capsular tension rings [35e39], soft contact lenses [40] and artificial skin [41] . It has also been studied commonly as an ophthalmological carrier of drugs such as pilocarpine [42] , Mitomycin C [43, 44] and 5-FU [45] . Consequently, HEMA and MMA cross-linked copolymer P(HEMA-co-MMA) was used as a carrier in this research.
In our previous research [46] , docetaxel was found to be a strong inhibitor of HLECs' proliferation (IC 50 : 16.48 ng/ml, 72 h). It could inhibit and delay G 2 /M phase transition of HLECs, induce HLECs' early apoptosis, and decrease the expression of bcl-2 protein. Therefore, docetaxel was chosen as the model drug in this research.
P(HEMA-co-MMA) with docetaxel was prepared and shaped into a ring, which could be inserted into ocular when ECCE surgery was carried out. After the drug was released, it could still play a role in supporting the capsular bag and preventing the capsular bag from shrinking.
2.
Materials and methods 
Materials
Synthesis methods
Docetaxel-loaded sustained-release preparations were synthesized by free radical solution polymerization method. Firstly, the monomer of HEMA, MMA and the cross-linker EGDMA were mixed together. Then the mixture was degassed by bubbling nitrogen for 30 min after AIBN initiator and docetaxel were added to it. Secondly, the solution was poured into a homemade mold. And finally, the polymerization reaction was performed in an oven at 60 C for 24 h.
Docetaxel-loaded sustained-release preparations with different MMA/HEMA ratios (mol/mol ¼ 1:9, 1.5:8.5, 2:8, 2.5:7.5 and 3:7) were prepared respectively. The pure P(HEMA-co-MMA) was synthesized without docetaxel.
Study on in-vitro drug release
Drug release experiments were conducted as follows: the docetaxel-loaded sustained-release preparations were put into containers containing 3 ml pH 7.4 phosphate buffered saline (PBS). The containers were shaken in a horizontally reciprocating shaker at 37 C (AE0.5 C). After being shaken for 1 day, the docetaxel-loaded sustained-release preparations were then transferred into other containers containing 3 ml fresh PBS respectively. Transfers were taken at 1d, 2d.16d, 18d.30d and 35d. Samples were detected by highperformance liquid chromatography (HPLC) and the HPLC methods were as follows: 50 mL liquids were injected for analysis. The mobile phase was acetonitrile/water (which equals 55/45), column temperature was 35 C, flow rate was 1 ml/min, and wavelength was 232 nm. The drug release behavior of docetaxel-loaded sustainedrelease preparations with different MMA/HEMA ratios (mol/
mol ¼ 1:9, 1.5:8.5, 2:8, 2.5:7.5 and 3:7) were studied by the same methods described above respectively.
Swelling ratio
The swelling properties of pure P(HEMA-co-MMA) were determined gravimetrically. Firstly the samples were placed in 5 ml DI water at room temperature. When their weight was stable after removing excess water, the samples were weighed on an electronic balance (92SM-202A, Precisa). And the samples were weighed on an electronic balance again after being dried by a drying vacuum oven at 60 C for 48 h. The swelling ratio was calculated by the following equation:
W w represents the wet weight of the sample; W d represents the dry weight of the sample.
Characterization of docetaxel-loaded sustainedrelease preparations
The IR spectra of the samples were recorded on an FTIR spectrometer (EQUINOX 55, Bruker, German) using KBr discs. The spectra were recorded from 4000 cm À1 to 500 cm
À1
. Powder X-ray diffraction measurements were carried out on D/Max-IIIA (Rigaku, Japan) with Cu, 35 KV and 25 mA. The DS/SS was 1 . The analysis was performed with 2q varying from 3 to 60 at a scan speed of 12 /min.
The microstructure of samples was studied with Scanning Electron Microscopes (JSM-6330F, Jeol, Japan). Samples were cracked in liquid nitrogen with 15 kV accelerating voltages.
2.6.
Biocompatibility studies of P(HEMA-co-MMA)
According to the national standard GB/T 16886, the cytotoxicity of one-month leaching liquor of homemade P(HEMA-co-MMA) (MMA mol /HEMA mol ¼ 9:1, 8.5:1.5, 8:2, 7.5:2.5, 7:3) was evaluated on L-929 cells. Phenol (6.3%) and culture medium (DMEM with 20% FBS, DMEM (20)) were used as positive and negative control groups respectively. Cells with samples were incubated together in a 96-well plate for 48 h. Then the samples were removed and 20 ml MTT solution (5 mg/ml, final concentration) was added. 4 h later, the MTT solution was removed and 150 ml DMSO was added to dissolve the blue MTT formazan precipitate. The absorbance of each well (OD) was measured at 490 nm with an ELISA Reader (Elx800, BIO-TEK, USA). The viability was calculated from the absorbance ratios of the sample group to the control group.
Studies on in-vitro pharmacodynamics
HLECs were cultured in a 24-well plate (1*10 4 cells/ml) at 37 C for 24 h, then the medium was changed and the docetaxel-loaded sustained-release preparations were hung in the well of the plate by a stainless steel wire in order that the preparations could be immersed in the culture solution without touching the cells. Then after incubated at 37 C for 2 days, the docetaxelloaded sustained-release preparations were transferred into another 24-well plate containing HLECs. Transfers were taken at 2d, 4d,., 20d, respectively. The concentration of docetaxel in DMEM (20) was then determined by HPLC. HPLC methods were the same as above. The in-vitro effect of inhibiting HLECs proliferation by docetaxel-loaded sustained-release preparations was evaluated through MTT assay in this part. Firstly, 200 ml MTT solution (5 mg/ml, final concentration) was added to the 96-well plate for each well and the cells were incubated continually for 4 h. After the MTT solution was removed, MTT formazan precipitate was dissolved in 750 ml DMSO. The absorbance of each well was measured at 490 nm with an ELISA Reader (Elx800, BIO-TEK, USA). The cell viability was calculated by the absorbance ratios of the sample group to the control group.
Results and discussion
Synthesis methods
The docetaxel-loaded sustained-release preparations and the pure P(HEMA-co-MMA) were successfully synthesized in cross-linking polymerization procedure. HEMA and MMA are monomers used to synthesize pHEMA, pMMA and P(HEMAco-MMA). EGDMA is commonly used as a cross-linking agent in synthesizing P(HEMA-co-MMA).
There are always two methods for loading drugs into P(HEMA-co-MMA). One is that the drug solution is absorbed into the pure polymer due to different distribution coefficients between polymer and water [47, 48] . The other is dissolving or suspending the drug into the mixture of monomer at the beginning of the polymerization procedure [42, 49] . Drug usually releases very fast from the preparations made by the first method [48] , while temperature-sensitive drugs are not suitable to be used by the second method. For the purpose of obtaining sustained-release preparations, the second method was employed in our research.
Release mechanism investigation
With a constant amount of cross-linker, the release rate of docetaxel could be retarded by increasing the ratio of MMA/ Fig. 1 e Effects of different MMA/HEMA ratios on in-vitro docetaxel release (0.3% EGDMA) (n [ 3). (Fig. 1) . On the first day, the release percentage of docetaxel decreased from 38.5% to 2.0% as the MMA/HEMA ratio increased from 1:9 to 3:7. On the twentieth day, there are about three-quarters of docetaxel released from the sustained-release preparations with an MMA/HEMA ratio of 1:9, but less than 10% docetaxel was released from the sustained-release preparations with an MMA/HEMA ratio of 3:7 (Fig. 2) . Zero-order kinetics, first-order kinetics, the Higuchi model and Peppas equation were used to investigate docetaxel release mechanism from the sustained-release preparations. According to the correlation coefficient (r 2 ), the fitting results showed that the release curves of docetaxel-loaded sustainedrelease preparations with MMA/HEMA ratios of 1:9, 1.5:8.5 and 2.5:7.5 fitted the Higuchi model (Table 1a, The release behavior of docetaxel-loaded sustainedrelease preparations in PBS (pH 7.4) was shown in Fig. 3 . The release rate gradually slowed down with an initial burst release in the first five days. The concentration of docetaxel on the first day was 3e4 times higher than that on the thirtieth day especially. What's more, the concentrations of docetaxel in pH 7.4 PBS were much higher than the IC 50 of docetaxel at 72 h at all release times, which indicated that the concentration of docetaxel released in vitro could maintain an effective concentration.
Docetaxel-loaded sustained-release preparations with different EGDMA ratio (v/v ¼ 0.3%, 1%, 2%, 6%, 8% and 10%) all fitted the Higuchi model very well (Table 2a, Studies on in-vitro drug release could not reflect the in-vivo drug release characteristics directly. But until now, there is no practicable method specially used for intraocular drug release studies. Therefore, according to the pertinent literature [49] , pH (about 7.4) and flow rate (2 w 3 ml/min) of the aqueous humor, 3 ml PBS (pH 7.4) was adopted as a release medium and the effects of different MMA/HEMA ratios and EGDMA content on in-vitro release behavior of docetaxel from the sustained-release preparations were studied.
The Higuchi model, which was the best fitting model, suggested that the pure diffusion procedure was the main drug release mechanism from these sustained-release preparations [50, 51] . According to the correlation equations Fig. 3 e The concentration diagram of in-vitro release of docetaxel-loaded sustained-release preparations (n [ 3).
a s i a n j o u r n a l o f p h a r m a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 2 5 2 e2 6 0 between k and R and the correlation equations k and W, specific preparations with expectable release of docetaxel could be designed and made. These correlation equations provided a theoretical basis for designing and preparing the docetaxelloaded sustained-release preparations in the future.
Swelling ratio
The swelling ratios decreased as the MMA/HEMA ratios increased. The swelling ratio of P(HEMA-co-MMA) was 55% when the MMA/HEMA ratio was 1:9; but when the MMA/HEMA ratio increased to 3:7, the swelling ratio was only 33% (Fig. 4) . At the same time, the release of docetaxel from the sustainedrelease preparations also decreased obviously. The reason was that there were many hydrophilic groups (eOH) in HEMA, so when the MMA ratio in P(HEMA-co-MMA) increased, the hydrophilicity decreased, which caused the drug release rate to slow down. Cross-linker EGDMA could enhance the density of P(HEMA-co-MMA), which also slowed down the drug release rate [42] .
Characterization of docetaxel-loaded sustainedrelease preparations
The FT-IR spectrum (4000e500 cm
À1
) was employed to analyze the form of docetaxel entrapped in P(HEMA-co-MMA). The stretching vibration of NeH at 3383 cm À1 and 3335 cm À1 and the out-plane vibration of NeH at 708 cm À1 (Amide Ⅴ band)
were the characteristic absorption band of docetaxel. However, these NeH absorption bands disappeared in P(HEMA-co- 
MMA) (Fig. 5b) . The characteristic absorption band of NeH existed in both docetaxel (Fig. 5a ) and the mixture of docetaxel and P(HEMA-co-MMA) (Fig. 5c ), but it also disappeared in FT-IR spectra of docetaxel-loaded sustained-release preparations (Fig. 5d) . These results indicated that a hydrogen bonding was formed by the interaction of the NeH of docetaxel and the eOH or C]O groups of P(HEMA-co-MMA).
The hydrogen bond between docetaxel and P(HEMA-co-MMA) could improve the compatibility between drug and polymer. No other chemical bond was formed between them, which suggested that the activity of docetaxel did not change.
The X-ray diffraction was employed to measure the crystalline property of docetaxel entrapped in P(HEMA-co-MMA). The characteristic diffraction peaks of docetaxel were 2q ¼ 5.2 , 9.8 , 13.7 , 15.7 , 20.2 . These characteristic diffraction peaks existed in both docetaxel and the mixture of docetaxel and P(HEMA-co-MMA), but disappeared in docetaxel-loaded sustained-release preparations (Fig. 6 ).
These results indicated that docetaxel dispersed in P(HEMAco-MMA) in the form of amorphism or molecule. Scanning electron micrographs showed that there was no gross difference between pure P(HEMA-co-MMA) and docetaxelloaded P(HEMA-co-MMA) (Fig. 7) , which suggested that the internal structure of P(HEMA-co-MMA) did not change when loaded with docetaxel. The SEM results also showed that there was no poriform structure on the surface of the sustainedrelease preparations after release (Fig. 8) , thus it wouldn't affect the integrality and morphology of the preparations. So it could still support the capsular bag and prevent the capsular bag from shrinking after the drug was released completely.
3.5.
The normal L-929 cells grew adherently and did not show significant morphological changes when cultured with test groups, and the viability of L-929 cells was more than 90%. 
While cultured with phenol, the cells floated and died and the cell viability was only 9.11% (Table 3) . P(HEMA-co-MMA) is a kind of non-degradation material, which has been widely used in medicine, but it is still necessary to investigate the biocompatibility of P(HEMA-co-MMA) made by ourselves. Results showed that the test groups had a reactivity grade of zero or one, and the positive control group's reactivity grade was four (Table 4 ). These indicated that the homemade P(HEMA-co-MMA) had good biocompatibility.
3.6.
Studies on in-vitro pharmacodynamics
HLECs were cultured to evaluate the inhibitory effect of the docetaxel-loaded sustained-release preparations. When treated with drug-loaded preparations, the viabilities of HLECs were less than 20% within 20 days, especially in the first eight days, and the viabilities of HLECs were less than 10% (Fig. 9) . These results proved that docetaxel-loaded sustained-release preparations could inhibit HLECs proliferation for at least 20 days. And docetaxel could be released for at least one month from these preparations in DMEM (20) .
The release results of docetaxel in DMEM (20) and pH 7.4 PBS showed that the release rate of docetaxel in PBS had a good liner correlation with that in DMEM (20) . The regression equations was y ¼ 1.2165xÀ15.241 (MMA/HEMA ¼ 1:9, r ¼ 0.9727 ( p < 0.01)), which indicated a positive correlation between them.
In the in-vitro pharmacodynamics studies, the docetaxelloaded sustained-release preparations were immersed in the culture solution without touching the cells. In the biocompatibility studies of P(HEMA-co-MMA), the results had already shown that the polymer was non-toxic, so the antiproliferative agent must have been released effectively from the polymer [44] . In the in-vitro pharmacodynamics studies, the inhibitory effect of the docetaxel-loaded sustained-release preparations proved to be constant and effective, especially on the second, fourth, eighth and tenth day.
In the in-vitro drug release studies, the concentrations of docetaxel in release media were much higher than its IC 50 in According to USP, the sample will meet the requirements of the test if the response to the Sample Preparation is not greater than grade 2 (mildly reactive). Fig. 9 e MTT analysis of cell viability after treated with docetaxel-loaded sustained-release preparations of different MMA/ HEMA ratios (n [ 3).
a s i a n j o u r n a l o f p h a r m a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 2 5 2 e2 6 0 the first five days and were always higher than the IC 50 (16.48 ng/ml, 72 h) of docetaxel at all times. The drug could be released from the docetaxel-loaded sustained-release preparations stably in DMEM (20) and the release rate of docetaxel in DMEM (20) had a positive correlation with that in PBS (pH 7.4). According to the pathogenesis and clinical experiences, a higher inhibitor concentration is necessary to clear LECs at the initial stages after surgery, when the proliferation and migration of LECs is extremely active. So it is necessary that the drug should be quickly released from the docetaxel-loaded sustained-release preparations and has a high inhibition rate during the first ten days. Furthermore, PCO is unlikely to occur if proliferation and transplant of the rudimental LECs don't occur. Thus, the initial burst release is beneficial for the prevention of PCO. However, in-vivo pharmacodynamics studies are still needed to prove whether the concentration of drug can reach therapeutic levels and whether it is toxic to other intraocular tissues.
Conclusion
In our research, the in-vitro pharmacodynamics experiments indicated that HLECs were sensitive to docetaxel and the docetaxel-loaded sustained-release preparations could maintain an effective drug concentration for up to 20 days. Owing to the limitations that in the present studies, only invitro experiments were conducted for the proposed preparation, further experiments would be conducted to study the correlation between the in-vitro experiments and the in-vivo experiments. This system and the preparations had very high potential for future clinical application.
